Renin inhibitor

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Renin inhibitors

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Antihypertensively active substances (reserve antihypertensive) that bind to the enzyme renin produced by the kidney and thus prevent the conversion of angiotensinogen into angiotensin I. The levels of angiotensin II and aldosterone decrease.

Pharmacodynamics (Effect)This section has been translated automatically.

The Renin-Angiotensin-Aldosterone System (RAAS) regulates the fluid and electrolyte balance in the body and thus influences blood pressure. The RAAS consists of various components, all of which are closely interrelated. The enzyme renin (endopeptidase) produced in the juxatglomerular cells of the kidney cleaves angiotensinogen into angiotensin I, which is subsequently converted into angiotensin II. Angiotensin II causes an increased release of aldosterone. Aldosterone causes a retention of sodium and water in the kidney. Angiotensin II has a blood pressure-increasing effect via vasoconstriction and volume increase within the vessels.

Renin inhibitors selectively block the endopeptidase renin. The conversion of angiotensinogen into angiotensin I is prevented. Thus, the level of angiotensin II and aldosterone decreases. Although the concentration of renin increases when taking renin inhibitors, its activity decreases. This mode of action is the biggest difference between renin inhibitors and ACE inhibitors or AT II blockers. Furthermore, sodium is reduced and retained in the kidney, while potassium is excreted in the urine to a lesser extent. Remarkably, the main representative of the reni inhibitors, aliskiren antiproliferative and antiinflammatory (inhibition of TNF-alpha and interleukin -6: beneficial effect on psoriatic skin changes - Pawloski PL et al. 2018)

Dosage and method of useThis section has been translated automatically.

Renin inhibitors are used to treat forms of hypertension that are caused by the adrenal gland's increased production of aldosterone. This form of hypertension affects about 50% of all patients with hypertension. Renin inhibitors must be taken regularly to lower blood pressure. It should be noted that the active ingredient is less easily absorbed in high-fat foods.

Undesirable effectsThis section has been translated automatically.

Diarrhoea, undesirable chronic cough (somewhat less frequent than with ACE inhibitors).

Other potential ADRs of renin inhibitors:

Nausea, vomiting, fatigue, headaches, upper respiratory tract infections, back and joint pain, undifferentiated "rashes".

Angioedema: the risk of developing angioedema is slightly lower than that of ACE inhibitors, but 3 times higher than that of beta-blockers (Toh S et al. 2012)

PreparationsThis section has been translated automatically.

Al risk viruses (Rasilez®: average daily dose 150-300mg/p.o.)

Note(s)This section has been translated automatically.

Renin inhibitors should be avoided in cases of diabetes mellitus, chronic urticaria or angioedema as well as reduced kidney function. The combination of a renin inhibitor with an ACE inhibitor should be avoided

LiteratureThis section has been translated automatically.

  1. Pawloski PL et al (2018) Aliskiren: Preclinical evidence for the treatment of hyperproliferative skindisorders. Biomed Pharmacother 104:151-157.
  2. Toh S et al (2012) Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Internal Med 172:1582-1589.

Authors

Last updated on: 29.10.2020